These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37717217)

  • 1. Brief report: Synthetic cannabinoid use among military personnel.
    Stogner J; Santangelo O; Baldwin JM
    Am J Addict; 2024 Jan; 33(1):96-99. PubMed ID: 37717217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 'Spice' Use Motivations, Experiences, and Repercussions among Veterans of the United States Armed Forces.
    Stogner J; Baldwin JM; Wiercioch A
    Subst Use Misuse; 2024; 59(8):1182-1189. PubMed ID: 38548662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does cannabis testing in the military drive synthetic cannabinoid use? Self-reported use motivations among justice-involved veterans.
    Santangelo O; Baldwin JM; Stogner J
    Int J Drug Policy; 2022 Aug; 106():103756. PubMed ID: 35738030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabis and Cannabinoids for Pain and Posttraumatic Stress Disorder in Military Personnel and Veterans.
    Wolfgang AS; Hoge CW
    JAMA Psychiatry; 2023 Sep; 80(9):869-870. PubMed ID: 37436761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A survey of synthetic cannabinoid consumption by current cannabis users.
    Gunderson EW; Haughey HM; Ait-Daoud N; Joshi AS; Hart CL
    Subst Abus; 2014; 35(2):184-9. PubMed ID: 24821356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic cannabinoid and cathinone use among US soldiers.
    Berry-Cabán CS; Kleinschmidt PE; Rao DS; Jenkins J
    US Army Med Dep J; 2012; ():19-24. PubMed ID: 23007932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychosis and synthetic cannabinoids.
    Deng H; Verrico CD; Kosten TR; Nielsen DA
    Psychiatry Res; 2018 Oct; 268():400-412. PubMed ID: 30125871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First episode psychosis with and without the use of cannabis and synthetic cannabinoids: Psychopathology, global functioning and suicidal ideation and antipsychotic effectiveness.
    Ricci V; Ceci F; Di Carlo F; Di Muzio I; Ciavoni L; Santangelo M; Di Salvo G; Pettorruso M; Martinotti G; Maina G
    Psychiatry Res; 2023 Feb; 320():115053. PubMed ID: 36682093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample.
    Winstock A; Lynskey M; Borschmann R; Waldron J
    J Psychopharmacol; 2015 Jun; 29(6):698-703. PubMed ID: 25759401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the experience of using synthetic cannabinoids by means of interpretative phenomenological analysis.
    Kassai S; Pintér JN; Rácz J; Böröndi B; Tóth-Karikó T; Kerekes K; Gyarmathy VA
    Harm Reduct J; 2017 Feb; 14(1):9. PubMed ID: 28187774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabis, cannabinoids, and health.
    Lafaye G; Karila L; Blecha L; Benyamina A
    Dialogues Clin Neurosci; 2017 Sep; 19(3):309-316. PubMed ID: 29302228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A preliminary evaluation of synthetic cannabinoid use among adolescent cannabis users: Characteristics and treatment outcomes.
    Blevins CE; Banes KE; Stephens RS; Walker DD; Roffman RA
    Addict Behav; 2016 Dec; 63():114-9. PubMed ID: 27454353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinoids and synthetic cannabinoids as a cause of death: Trends and their healthcare implications.
    Suriaga A; Tappen RM; Aston ER; Chiang-Hanisko L; Newman D
    J Nurs Scholarsh; 2023 May; 55(3):623-636. PubMed ID: 36250599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic cannabinoid use among college students.
    Mathews EM; Jeffries E; Hsieh C; Jones G; Buckner JD
    Addict Behav; 2019 Jun; 93():219-224. PubMed ID: 30772774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of the many faces of synthetic cannabinoid toxicities.
    Alipour A; Patel PB; Shabbir Z; Gabrielson S
    Ment Health Clin; 2019 Mar; 9(2):93-99. PubMed ID: 30842917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis.
    Mensen VT; Vreeker A; Nordgren J; Atkinson A; de la Torre R; Farré M; Ramaekers JG; Brunt TM
    Psychopharmacology (Berl); 2019 Sep; 236(9):2677-2685. PubMed ID: 30968175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic Cannabis Substances (SPS) Use and Hallucinogen Persisting Perception Disorder (HPPD): Two Case Reports.
    G Lerner A; Goodman C; Bor O; Lev-Ran S
    Isr J Psychiatry Relat Sci; 2014; 51(4):277-80. PubMed ID: 25841224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic Cannabinoid Use in a Psychiatric Patient Population: A Pilot Study.
    Welter S; Lücke C; Lam AP; Custal C; Moeller S; Sörös P; Thiel CM; Philipsen A; Müller HHO
    Eur Addict Res; 2017; 23(4):182-193. PubMed ID: 28848170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential physiological and behavioral cues observed in individuals smoking botanical marijuana versus synthetic cannabinoid drugs.
    Chase PB; Hawkins J; Mosier J; Jimenez E; Boesen K; Logan BK; Walter FG
    Clin Toxicol (Phila); 2016; 54(1):14-9. PubMed ID: 26653952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EMCDDA framework and practical guidance for naming synthetic cannabinoids.
    Pulver B; Fischmann S; Gallegos A; Christie R
    Drug Test Anal; 2023 Mar; 15(3):255-276. PubMed ID: 36346325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.